Actively Recruiting
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
Led by Azienda Ospedaliera Universitaria Integrata Verona · Updated on 2023-05-10
165
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective is the evaluation of the prognostic value of ctDNA (circulating tumor DNA) as a marker of surgical futility in patients with operable PDAC.
CONDITIONS
Official Title
Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with pancreatic ductal adenocarcinoma (PDAC) planned for surgical resection, including upfront surgery or after induction treatment
- Non-metastatic status confirmed by abdominal CT scan
- Able to provide informed consent
- Age 18 years or older
You will not qualify if you...
- Patients initially planned for surgery but found unresectable due to advanced disease or contraindications during surgery
- Uncontrolled congestive heart failure
- Untreated angina
- Recent heart attack within the past year
- Uncontrolled high blood pressure (systolic >160 mm Hg or diastolic >100 mm Hg, despite treatment)
- Long QT syndrome
- Major uncontrolled infections
- Severe liver failure
- Under 18 years of age
- Informed consent not signed
- Pregnant or breastfeeding women and women of child-bearing age not using effective contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
AOUI Verona
Verona, Italy, 37134
Actively Recruiting
Research Team
A
antonio pea, MD PHD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here